SkinVision Unveils Breakthrough Algorithm that Takes the Fight to Skin Cancer

Dutch mobile health startup SkinVision has revealed its new algorithm that can detect most common forms of deadly skin cancer. Previously focused on detecting melanoma skin cancer, the app can now identify Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) too, the first app ever to do that.

Across the world, more than one billion people are at risk of developing skin cancer at some point in their lives. Helping them prepare is a selected group of dermatologists. For example 10,000 in the US and only 550 in the UK. SkinVision’s new algorithm will help provide people with a means to assess moles for risk indication on demand to save time and lives. Users can download the app for free and can perform a number of free assessments as well.

There is a seamless connection between users and their doctors to monitor skin lesions with a personal archive that can be used as reference during visits, saving time and improving efficiency for dermatologists.

"Our mission is to empower people to early detect skin cancer, which is highly important for possible treatment options," says SkinVision founder and CEO Erik de Heus. "We aim to save 250,000 lives in the next decade."

Melanoma is a type of skin cancer that forms in the cells responsible for skin pigmentation, known as melanocytes. Although it is less common than other forms of skin cancer, it is much more aggressive. In the United States alone, melanoma accounts for more than, 10,000 of the 13,000 deaths caused by skin cancer each year. Research shows that 5,4 million non-melanoma skin cancer cases are identified every year in the US.

SkinVision has now expanded its remit to identify and alert people to these non-melanoma cancers, like BCC and SCC cancers, too.

"Our new algorithm can recognize nine in every 10 cases of deadly skin cancer," de Heus continues. "This is because our latest research shows 88 per cent sensitivity towards melanoma skin cancer. Our work has been scientifically tested in the leading dermatology clinic at Ludwig-Maximilians-Universitat Clinic in Munich, Germany."

SkinVision is available for both iPhone and Android (Samsung S4 and up only for now) here. The app can be used worldwide except in the US, although the company indicates it will be arriving there soon.

For further information, please visit:
http://skinvision.com

About SkinVision
SkinVision is a Dutch health startup based in Amsterdam. SkinVision's newest algorithm helps health conscious people to identify Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) skin cancers, as well as more aggressive melanoma varieties.

Most Popular Now

Do Fitness Apps do More Harm than Good?

A study published in the British Journal of Health Psychology reveals the negative behavioral and psychological consequences of commercial fitness apps reported by users on social media. These impacts may...

AI Tool Beats Humans at Detecting Parasi…

Scientists at ARUP Laboratories have developed an artificial intelligence (AI) tool that detects intestinal parasites in stool samples more quickly and accurately than traditional methods, potentially transforming how labs diagnose...

Making Cancer Vaccines More Personal

In a new study, University of Arizona researchers created a model for cutaneous squamous cell carcinoma, a type of skin cancer, and identified two mutated tumor proteins, or neoantigens, that...

AI can Better Predict Future Risk for He…

A landmark study led by University' experts has shown that artificial intelligence can better predict how doctors should treat patients following a heart attack. The study, conducted by an international...

A New AI Model Improves the Prediction o…

Breast cancer is the most commonly diagnosed form of cancer in the world among women, with more than 2.3 million cases a year, and continues to be one of the...

AI System Finds Crucial Clues for Diagno…

Doctors often must make critical decisions in minutes, relying on incomplete information. While electronic health records contain vast amounts of patient data, much of it remains difficult to interpret quickly...